Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

GENERAL COMPANY INFORMATION
- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 8,900 employees in the U.S., UK and EU
- 2019 R&D investment of nearly $2.5 billion

LOCATIONS
- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
- Dublin, Ireland and London, UK: Global business offices

FDA-APPROVED & MARKETED MEDICINES

- **Arcalyst** (rilonacept) Injection for Subcutaneous Use
- **Dupixent** (dupilumab) Injection
  - 200mg
  - 300mg
- **Eylea** (afibercept) Injection
- **Kezara** (sarilumab) injection
  - 150 mg
  - 200 mg
- **Inmazeb** (atoltivimab, maftivimab, and odesivimab - ebgn) Injection
- **Praluent** (alirocumab) Injection
  - 75mg/mL
- **Libtayo** (cemiplimab-rwlc) Injection
  - 350 mg

*U.S. Food and Drug Administration
CLINICAL PRODUCT CANDIDATES

**PHASE 1**

- **CEMIPLIMAB**
  - PD-1 Antibody | Cancer
- **REGN3767**
  - LAG-3 Antibody | Cancer
- **REGN6569**
  - GITR Antibody | Cancer
- **ODRONEXTAMAB**
  - CD20 X CD3 Antibody | Cancer
- **REGN4018**
  - MUC16 X CD3 Antibody | Cancer
- **REGN5459**
  - BCMA X CD3 Antibody | Cancer
- **REGN5678**
  - PSMA X CD3 Antibody | Cancer
- **REGN5093**
  - MET X MET Antibody | Cancer
- **REGN5713**
  - Btk x 1 Antibodies | Birch allergy
- **REGN7257**
  - IL13Rg Antibody | Aplastic anemia
- **CASIRIVIMAB + IMDEVIMAB**
  - SARS-CoV2 Virus Multi-Antibody Therapy
- **REGN5381**
  - NRP1 Agonist Antibody | Heart failure

**PHASE 2**

- **AFLIBERCEPT**
  - VEGF-Trap | High dose (8mg) for wet age-related macular degeneration (AMD)
- **CEMIPLIMAB**
  - PD-1 Antibody | Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
- **ODRONEXTAMAB**
  - CD20 X CD3 Antibody | B-cell non-Hodgkin lymphoma
- **REGN4461**
  - LEPR Agonist Antibody | Generalized lipodystrophy

**PHASE 3**

- **CEMIPLIMAB**
  - PD-1 Antibody | Non-small cell lung cancer (NSCLC), adjuvant cutaneous squamous cell carcinoma (CSCC)
- **CASIRIVIMAB + IMDEVIMAB**
  - SARS-CoV2 Virus Multi-Antibody Therapy | Treatment and prevention of COVID-19

*In collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

LEADERS IN TECHNOLOGY

- **Fully human monoclonal antibodies**: Regeneron has developed a suite of patented technologies (VelociSuite®), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.
- **Fusion proteins**: Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.
- **Regeneron Genetics Center**: A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.